Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

Hepatitis B news

Show

From To
HIV/HBV co-infection linked to worse immune recovery and death, but tenofovir improves outcomes

HIV-positive people with hepatitis B virus (HBV) co-infection had impaired CD4 cell recovery after starting antiretroviral therapy (ART) and a higher risk of death than those without

Published
23 May 2016
By
Liz Highleyman
Interferon-based therapy improves clinical outcomes in hepatitis delta infection

Patients with hepatitis delta virus infection treated with pegylated interferon alpha were less likely to develop clinical outcomes — like decompensation or hepatocellular carcinoma — compared with patients who received nucleos(t)ide based treatment or no treatment at all, according to a presentation at International Liver Congress.

Published
22 April 2016
From
Healio
Tenofovir alafenamide works well against hepatitis B with less effect on bones and kidneys

The new tenofovir alafenamide (TAF) pro-drug is as potent against hepatitis B virus (HBV) as the current tenofovir disoproxil fumarate (TDF) formulation, but with fewer detrimental effects

Published
18 April 2016
By
Liz Highleyman
ContraVir's CMX157 Outperforms Gilead's Tenofovir AF (TAF) Against Hepatitis B Virus in Independent Head-to-Head In-Vitro Study

Viral rebound studies showed that CMX157 demonstrates best-in-class duration of activity. Nine days following incubation with HBV, using two different experimental conditions, one at equimolar and one at EC90 concentrations, CMX157 showed two- to three-fold reduced viral rebound compared to TAF.

Published
30 March 2016
From
ContraVir press release
Opt-out HIV/HBV/HCV testing for patients attending emergency departments identifies significant number of new infections

A week-long pilot study involving nine UK emergency departments has shown that routine, opt-out testing for HIV, hepatitis B virus (HBV) and hepatitis C virus (HCV) can

Published
22 March 2016
By
Michael Carter
Life expectancy in HIV-positive people in the US still lags 13 years behind HIV-negative people

A study presented at the Conference on Retroviruses and Opportunistic Infections (CROI 2016) comparing life expectancies of HIV-positive and HIV-negative people within the Kaiser Permanente health insurance

Published
28 February 2016
By
Gus Cairns
Survey shows more than 800,000 people in US have hepatitis B, half of them Asian

Although nearly 70 million people in the US have been vaccinated against hepatitis B virus (HBV), there are still 847,000 people with evidence of infection, about 400,000

Published
22 February 2016
By
Liz Highleyman
D:A:D study: long-term treatment with tenofovir associated with increased risk of serious liver disease

Long-term therapy with the antiretroviral drug tenofovir increases the risk of end-stage liver disease and liver cancer, according to data from the D:A:D study published

Published
21 January 2016
By
Michael Carter
High rates of modifiable cancer risk factors present in Western HIV-positive patients

The prevalence of potentially modifiable risk factors for some cancers is “extraordinarily high” among people with HIV, according to results of a meta-analysis published in

Published
18 January 2016
By
Michael Carter
J&J signs deal with Chinese company for hepatitis B drug

The deal with Sino's Chia Tai Tiaqing Pharmaceutical unit includes an immune-stimulating agent that could potentially be combined with antiviral drugs J&J acquired when it purchased Novira Therapeutics in November. Hepatitis B has been difficult to cure because antiviral medicines that block replication of the virus have proved insufficient at clearing it from the blood. J&J and other researchers believe an assault by components of the immune system will be needed as part of a cure.

Published
08 January 2016
From
Reuters
← First12345...15Next →

Filter by country